$4.50
-0.02 (-0.44%)
Open$4.47
Previous Close$4.52
Day High$4.58
Day Low$4.38
52W High$75.50
52W Low$4.68
Volume—
Avg Volume52.4K
Market Cap19.27M
P/E Ratio—
EPS$-0.21
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+365.8% upside
Current
$4.50
$4.50
Target
$20.96
$20.96
$15.05
$20.96 avg
$24.54
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 26.00M | 22.93M | 28.87M |
| Net Income | -3,802,417 | -3,978,629 | -3,915,216 |
| Profit Margin | -14.6% | -17.4% | -13.6% |
| EBITDA | -5,256,206 | -4,739,765 | -5,087,055 |
| Free Cash Flow | -3,224,852 | -2,115,724 | -2,331,954 |
| Rev Growth | +20.6% | +0.2% | +12.7% |
| Debt/Equity | 0.27 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |